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Abstract
Background: Oral pre-exposure prophylaxis (PrEP) is a daily medication that can prevent HIV
infection. PrEP may further support HIV prevention initiatives in Thailand, particularly as it becomes
more accessible in the country’s government clinics and hospitals. While studies have explored
perceptions of PrEP for at-risk people in Thailand, there has been limited investigation into Thai
physicians’ opinions on and willingness to prescribe PrEP.
Methods: Using convenience sampling, this cross-sectional study recruited 132 Thai physicians to
complete an anonymous, online survey. The survey assessed physicians’ concerns about PrEP,
experience with PrEP, and willingness to prescribe PrEP. Bivariate and multivariable logistic
regressions were conducted to assess factors associated with willingness to prescribe.
Results: The majority of the sample had heard of PrEP before the survey (81.1%) and were willing to
prescribe it (68.2%), though a minority had experience prescribing (18.2%). Common concerns
regarding PrEP included the potential for decreased condom use, antiretroviral resistance, inadequate
patient compliance, medication side effects, and an increase in STIs. The most frequently reported
barrier to prescribing was a lack of clinical knowledge of PrEP. In a multivariable model, believing
that PrEP was essential for addressing the HIV epidemic (aOR=20.87; 95% CI=3.69-118.12) and
being willing to attend continuing medical education on PrEP (aOR=9.46; 95% CI=3.27-27.36) were
associated with significantly higher odds of being willing to prescribe PrEP.
Conclusion: This is the first study to assess Thai physicians’ willingness to prescribe PrEP. While the
majority of our sample expressed willingness to prescribe, our results indicate a need to strengthen
and promote medical education on PrEP to improve physicians’ knowledge of the medication and
confidence in its safety and effectiveness. Public health messaging should also address physicians’
concerns about risk compensation following PrEP initiation and should further emphasize the
potential importance of PrEP in reducing HIV incidence in Thailand.
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Background
The HIV epidemic in Thailand
Thailand is a middle-income country with a population of nearly 70 million people and an adult
HIV prevalence of approximately 1%—one of the highest national prevalences in Asia and the
Pacific.1 While incidence of HIV in Thailand has continued to decline each year, 5,400 new
infections occurred in 2019, with incidence highest among several key populations.1–3 For
example, it is estimated that approximately 50% of new infections occur among men who have
sex with men (MSM) and transgender people, 10% among sex workers (SW) and their clients,
and 12% among people who inject drugs (PWID).2,4 Additionally, sexual transmission accounts
for an estimated 90% of infections in Thailand.2 Incidence is further concentrated among
younger members of key populations where, for example, HIV incidence in Bangkok among
MSM aged 18 to 21 was 8.8 per 100 person-years compared to 3.7 per 100 person-years for
MSM over 30.5 While behavioral interventions such as condom use have aided in the reduction
of incidence, transmission within key populations still remains high even under national efforts
such as the 100% Condom Use campaign.6,7 This has signaled a need for additional prevention
strategies which can strengthen the country’s response to the epidemic.
Pre-exposure prophylaxis (PrEP)
Oral pre-exposure prophylaxis (PrEP) is a daily medication that can help prevent HIV infection
for people who are HIV negative. It is a single tablet containing two antiretroviral drugs,
Tenofovir and Emtricitabine, and is most commonly known under the brand name Truvada.8 The
medication’s efficacy was first recognized in 2010 in the iPrEX study which administered PrEP
to approximately 2,500 MSM and transgender women (TGW) in clinical sites around the world,
including in Thailand. While the results of this study demonstrated an overall efficacy of 45%,
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this was primarily due to low adherence among participants. For participants with a detectable
amount of the study drug in their system, PrEP had an efficacy over 90%.9 Similar efficacy has
been demonstrated in other pilot studies, including a trial conducted in Bangkok which examined
PrEP’s efficacy among PWID.10–12
Because of the promising results from such trials, in 2014 the national Thai Guidelines on HIV
Prevention and Care recommended PrEP as an additional HIV prevention method for people
who are at risk.13 Following this, several PrEP-delivery pilot programs in Thailand were
implemented to explore different strategies which could increase accessibility of the medication
for members of key populations. For example, the Thai Red Cross AIDS Research Center
implemented a fee-based PrEP provision system where participating high-risk individuals could
access PrEP, laboratory testing, and condoms for 30 Thai Baht (~1 USD) per day.6,14
Additionally, private clinics in Thailand such as the Pulse Clinic have focused on providing
sexual health care to LGBT+ patients and have been regional leaders in PrEP distribution.15 The
accessibility of PrEP in Thailand is further enhanced by the development of several locallyproduced generic versions of the medication which help make the drug more affordable.16–18
Through these strides in implementation initiatives and drug production, Thailand now has an
estimated 21,000-22,000 current PrEP users.16
Given the success of PrEP delivery in Thailand, along with the recognition that there are still
many people who could benefit from the medication, in 2020 PrEP provision was recently
included in the country’s universal healthcare scheme.16,18 This new policy has made PrEP
accessible in government facilities for free, a move which will likely help more vulnerable, atrisk individuals receive the medication. While this decision marks an impressive effort to further
scale-up PrEP provision, its impact can only be maximized through the widespread acceptance of
5

PrEP as a prevention method by both eligible individuals and the physicians who can provide
PrEP-related care in the coming years.
Acceptability of PrEP
Several studies have examined at-risk individuals’ acceptance of and willingness to use PrEP in
Thailand. For example, across studies, between 36-80% of Thai MSM and TGW have expressed
an interest in using PrEP.19–21 What is less known are Thai physicians’ opinions of PrEP and
their general willingness to prescribe it. This is a critical perspective to explore since physicians
often serve as gatekeepers to the medication and can make accessing PrEP more challenging if
they are either unwilling to prescribe it or if they have significant concerns about its use. To our
knowledge, there has never been a published study examining this subject in Thailand, though it
has been explored elsewhere in the world. For example, a number of studies assessing
physicians’ knowledge and opinions on PrEP, along with their willingness to prescribe it, have
been conducted in the United States as well as various other North American, South American,
and European countries.22–29 These studies have frequently found that while the majority of
surveyed physicians in recent years are aware of PrEP and support its use, a minority have
actually prescribed the medication. Additionally, common concerns about PrEP that physicians
have reported include the cost of the medication to the patient, the potential to develop
antiretroviral resistance, inadequate medical education on PrEP, an increase in patients’ risky
sexual behavior, and the potentially low “real-world” effectiveness of PrEP.22–27
While such studies offer some perspective on how willing physicians in Thailand may be to
prescribe PrEP, Thailand is unique in that it has been a pioneer in PrEP provision due to its
robust demonstration projects, its position as a regional hub for PrEP prescriptions, and its recent
inclusion of free PrEP in government facilities. These factors, along with a recognition of the
6

distinct cultural context that physicians in Thailand are operating in, signal a need to specifically
study Thai physicians’ perceptions of PrEP. This cross-sectional study aims to address the gaps
in our understanding of their concerns and beliefs about PrEP, along with their willingness to
prescribe it and the factors associated with willingness. Through this study, we hope to identify
possible avenues for intervention which can help strengthen physicians’ interest in prescribing
PrEP to at-risk patients of all identities.

Methods
Participants and procedures
A cross-sectional study of physicians was conducted from October 2020 to January 2021.
Participants (n=132) were recruited using convenience sampling via social media. Information
about the study along with a link to the survey were shared in several private Facebook groups
dedicated to Thai physicians, as well as through targeted Facebook advertisements. Inclusion
criteria for study participation were: 1) identifying as a medically licensed physician in Thailand;
and 2) providing medical care to at least one patient in the past 12 months.
Upon clicking the survey link, participants were presented with an information sheet that
described the study procedures and purpose. After reading this information sheet, participants
could provide their consent by responding affirmatively to a question asking if they agreed to
participate. All responses were anonymous, and study participants had the option to complete the
survey in either Thai or English. The survey required approximately 10-15 minutes to complete.
The survey was programmed and delivered using Qualtrics online survey software. All study
materials including the survey were originally created in English and subsequently translated into
Thai. The translation process involved multiple people who were fluent in both languages who
7

provided feedback on each other’s translations and came to an agreement about the final version
of the survey which was then programmed into Qualtrics. The survey was then piloted with
several Thai physicians to ensure all questions were understandable, that the survey used
appropriate clinical terms, and that the format of various survey questions was user-friendly.
Survey measures
The format of the survey and selection of various survey measures were informed by an original
survey which assessed Malaysian physicians’ knowledge of and willingness to prescribe PrEP.30
Several items from that survey were adapted for our survey to better reflect the Thai context. We
also further adapted items from this survey to allow for easier execution of our intended
analyses. This primarily involved changing several questions that had answers in a 5-level scale
to a 4-level scale so that relevant variables could be more easily transformed into a binary form
for regression analyses. Additionally, feedback from piloting the survey further refined our
design of survey measures.
Our survey began by providing participants with the following short description of PrEP:
“Pre-exposure prophylaxis, or ‘PrEP’, is a daily, oral medication that can prevent HIV infection
for people who are HIV-negative. The PrEP medication is a single tablet containing two
antiretroviral drugs, Tenofovir and Emtricitabine. Trade names include: Truvada, Tenvir-EM,
Ricovir-EM, Tenof-EM, Tavin-EM, and Teno-EM”
Participants were then asked if they had known about PrEP prior to the survey. If they had, they
were subsequently asked questions about where they had acquired information about PrEP,
whether they had experience prescribing, and how many patients they had prescribed to. The
survey further included questions that assessed physicians’ perceptions of PrEP such as their
8

beliefs about PrEP’s safety and effectiveness as well as whether they believed the medication
had an essential role in managing the HIV epidemic. Additionally, participants were asked about
their level of concern regarding Thailand’s HIV epidemic, their willingness to attend continuing
medical education (CME) on PrEP, and what they considered to be significant barriers or
concerns related to PrEP prescriptions.
General willingness to prescribe PrEP was assessed through a 4-level rating scale (4= “very
willing”, 3= “somewhat willing”, 2= “not very willing”, and 1= “unwilling”). Participants were
also asked to indicate the likelihood that they would prescribe to people from different
populations (e.g., MSM, PWID) through a 5-point rating scale (5= “very likely”, 4= “likely”, 3=
“neutral”, 2= “unlikely”, and 1= “very unlikely”). Similar 4- or 5-point scales have been used in
other studies assessing either physicians’ willingness to prescribe PrEP or people’s willingness to
use the medication.19,20,23,24
Participants’ attitudes towards MSM, TGW, PWID, SW, people living with HIV, and general
medical patients were measured using “feeling thermometers” which required participants to
score their attitudes towards each population on a scale of 1 (very negative) to 100 (very
positive), with 50 being neutral. Feeling thermometers have been characterized as reliable survey
tools and have been used in other studies to assess attitudes towards those living with or at-risk
for HIV.30–32
Relevant sociodemographic and professional characteristics were also measured including
participants’ gender, age, years practicing medicine, medical specialty, and the medical setting
they primarily practice at (e.g., government clinic, private hospital).
Statistical analyses
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All analyses were completed using SAS version 9.4. Frequencies and descriptive statistics were
used to initially characterize the sample and to report the distribution of participants’ willingness
to prescribe PrEP and the potential concerns they had about the medication.
Pearson correlations were used to explore associations between attitudes towards each of the key
populations (MSM, TGW, SW, PWID) and the likelihood of prescribing PrEP to an individual
from that key population.
To further explore general willingness to prescribe PrEP, we dichotomized the 4-level
willingness variable such that those who answered that they were “unwilling” or “not very
willing” were coded as “unwilling”, and those that answered they were “somewhat willing” or
“very willing” were coded as “willing.” This variable transformation was done for ease of
interpretation, to help conduct desired analyses, and because the design of the 4-point scale
allowed for a natural construction of a binary option. Similar dichotomization of willingness can
be seen in other studies on related subjects.23–25,33 This binary willingness variable was used as
the primary outcome variable for a series of bivariate logistic regressions assessing potential
associations between willingness to prescribe PrEP and various sociodemographic/professional
variables, attitudes about PrEP, and attitudes towards specific populations. We then ran a
multivariable logistic regression analysis using independent variables with a statistical
significance at the p <0.05 level in the bivariate analyses. All variables were checked for
collinearity during the establishment of the final model. Odds ratios with 95% confidence
intervals were reported for all regression analyses.
For these regressions, several other variables were also dichotomized. For example, specialty
was dichotomized by comparing participants in medical fields that provide primary care services
(general practice, family medicine, and general internal medicine physicians) to those that were
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more specialized (primary care=1; else=0). Clinical setting was dichotomized by comparing
those working in government facilities to those practicing in private or university settings (public
sector =1; else=0). Similar to the recoding of the willingness-to-prescribe variable, willingness to
attend CME was made binary by recoding those who were “somewhat” and “very” willing as
“willing,” while those answering otherwise were recoded as “unwilling” (willing=1; else=0).
Those who believed PrEP was “very” safe and those who believed PrEP was “very” effective
were distinguished from those expressing less confidence in these claims (“very” = 1; else = 0).
Finally, those who were “very” concerned about the Thai HIV epidemic were compared to those
who expressed less concern (“very” = 1; else=0). These decisions were made after assessing the
distribution of respondents’ answers and because, from a conceptual standpoint, we wanted to
compare those who expressed high confidence in the safety/effectiveness of PrEP from those
who expressed more hesitancy over these statements, and we wanted to compare those who
expressed maximum concern over the epidemic from those who reported being less worried.
Ethics
The study protocol, survey, information sheets, and process for providing informed consent were
all approved by the Institutional Review Boards at both Yale University and Mahidol University.
To protect participants’ identities, the survey was anonymous and no questions required
participants to share personally identifiable information (e.g., email addresses, phone numbers,
names, etc.). No incentives were provided for survey completion.

Results
Description of sample
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The mean age of participants was 39.5 years (SD = 9.2), and the mean years practicing was 14.0
years (SD= 8.6) (Table 1). 50.8% of participants identified as men, 48.5% identified as women,
and 1 participant identified as a non-binary gender. The most represented medical specialties in
the sample were general practice (29.5%), family medicine (14.4%), and internal medicine
(11.4%). Private hospitals (19.7%) and teaching/university hospitals (16.7%) were the 2 most
common places of employment for participants. Overall, 48.5% of participants practiced in
government facilities, 31.8% practiced in private facilities, 16.7% practiced in a university or
teaching hospital, and 3.0% practiced in “other” settings. In terms of perceptions of the local
HIV epidemic, 38.6% of participants reported being very concerned about Thailand’s HIV
epidemic, 41.7% were somewhat concerned, 18.2% were a little concerned, and only 1.5% were
not concerned at all.
The majority of participants (81.1%) had known of PrEP prior to the survey. Of those who had
prior awareness of PrEP, participants reported acquiring information about the medication from a
variety of sources. These sources included medical school (57.9%), clinical practice guidelines
(46.7%), the Internet (43.9%), continuing medical education (29.0%), and colleagues (27.1%).
While a high proportion of participants had prior knowledge of PrEP, a minority of them had
ever prescribed it (18.2%). Of those who had previously prescribed PrEP, the most frequent
number of patients prescribed to was 5 (range: 1-100 patients). Additionally, even though the
majority of participants had no experience prescribing, 75.8% of all participants responded that
they would initiate a conversation about PrEP with a patient, and 85.6% agreed that PrEP was
essential for responding to Thailand’s HIV epidemic. 73.5% of participants were also at least
somewhat willing to attend CME on PrEP.
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Concerns and opinions about PrEP
The majority of participants believed PrEP was effective and generally safe. More specifically,
54.5% of participants believed PrEP was moderately effective, while 35.6% believed it was very
effective. All participants believed PrEP was at least slightly safe, with 62% perceiving it to be
moderately safe and 28.8% believing it to be very safe.
In terms of concerns about PrEP, all participants reported at least one concern about the
medication, and the majority of participants reported multiple. The most common concerns
participants reported include the potential for decreased condom use for patients on PrEP
(76.5%), the development of antiretroviral resistance (71.2%), patients’ ability to comply with
the medication (65.9%), medication side effects (62.1%), and an increase in STIs following PrEP
use (50.0%) (Figure 1). Additional concerns reported include concerns about the effectiveness of
PrEP (44.7%), the belief that patients will have more sex partners (44.7%), the potential toxicity
of PrEP (37.1%), patients’ ability to afford PrEP (15.2%), and the increase in follow-up visits
required for PrEP-related care (13.6%).
When asked about the single most significant barrier to prescribing PrEP if a participant wanted
to, the most common response was having insufficient clinical knowledge of PrEP (42.4%)
(Figure 2). Following this, other barriers were a perceived lack of clinical guidelines on PrEP
(19.7%), a lack of patient interest (15.9%), the cost of PrEP (13.6%), the increase in follow-up
visits required (4.6%), and “other” barriers (3.8%). These “other” barriers included perceived
difficulty prescribing in primary care settings, the inability of PrEP to prevent other STIs, a
desire to focus on promoting barrier methods for HIV prevention, and a concern about having to
diagnose patients with HIV if the medication failed.
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Willingness to prescribe PrEP
Overall, 68.2% of participants were at least somewhat willing to prescribe PrEP (39.4% very
willing; 28.8% somewhat willing). Of those who expressed less willingness to prescribe, 25.0%
reported being not very willing and 6.8% were completely unwilling (Figure 3).
In terms of physicians’ likelihood of prescribing PrEP to specific key populations, 87.1% of
participants responded that they were likely to prescribe PrEP to MSM, 81.1% were likely to
prescribe to TGW, and 83.3% were likely to prescribe to SW (Figure 4). The population that
physicians reported the lowest likelihood of prescribing to was PWID, with 66.7% of physicians
indicating that they were likely to prescribe.
Attitudes towards different key populations were significantly correlated with likelihood of
prescribing to that specific population (Table 2). For all populations examined, more positive
feelings towards a population were weakly correlated (as defined by r = 0.1-0.3) 34 with greater
likelihood of prescribing PrEP to a patient from that population.
Factors associated with general willingness to prescribe PrEP
At the bivariate level, participants who believed PrEP was essential for addressing the Thai HIV
epidemic (OR=29.92; 95% CI=6.47-138.28), believed PrEP was very safe (OR=2.63; 95% CI=
1.05-6.60), believed PrEP was very effective (OR=4.00; 95% CI= 1.61-9.96), had heard of PrEP
prior to the study (OR=4.44; 95% CI= 1.79-11.06), or who were willing to attend CME on PrEP
(OR=11.77; 95% CI= 4.79-28.97) had significantly increased odds of being generally willing to
prescribe PrEP compared to those who did not meet these criteria (Table 3). Additionally,
feelings towards those living with HIV had a marginally significant association with odds of
being willing to prescribe PrEP (OR=1.02; 95% CI= 1.00-1.04).
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In the multivariable model (Table 3), believing that PrEP was essential for addressing the Thai
HIV epidemic or being willing to attend CME were associated with significantly increased odds
of being willing to prescribe PrEP. Those who believed PrEP was needed to address the
epidemic had 20-fold higher odds of being willing to prescribe PrEP compared to those who did
not see PrEP as essential (OR= 20.87; 95% CI = 3.69-118.12). Participants who expressed
willingness to attend CME had 9-fold higher odds of being willing to prescribe PrEP compared
to those who were unwilling to attend CME (OR = 9.46; 95% CI= 3.27-27.36).

Discussion
To our knowledge, this is the first study to describe Thai physicians’ perceptions of PrEP and
their willingness to prescribe the medication. The majority of participants in our sample (68.2%)
are at least somewhat willing to prescribe PrEP, with over one third of the sample indicating they
are very willing to prescribe. Given the progress the country has made in scaling-up PrEP
provision and the medication’s recent inclusion in the universal healthcare scheme, it is
promising that a relatively high proportion of our sample are open to prescribing. These results
are comparable to findings from studies in other countries where the proportion of physicians
who are willing to prescribe range from 59.5% to 87%.23,24,28,29
Still, 31.8% of participants expressed an unwillingness to prescribe PrEP. This is a substantial
portion of our sample and indicates a need for interventions which can address hesitancy to
prescribe. When considering the various concerns and barriers participants cited about PrEP
prescription, one potential suggestion for enhancing willingness is improvements in medical
education, both within medical school and through CME. When asked about the single most
significant barrier that exists to prescribing, 42.4% of participants reported that it was a lack of
clinical knowledge of PrEP while 19.7% reported that it was a lack of clinical guidelines on
15

prescription. Additionally, while the majority of participants had heard of PrEP prior to the
study, 18.9% had not. These results are concerning given that Thailand has been a global leader
in PrEP delivery and demonstrations, while also providing physicians with information on PrEP
in clinical guidelines since 2014. As such, there is a clear need to improve the accessibility of
guidelines related to PrEP and a need to ensure that current medical education curriculums
provide comprehensive education on the medication during clinician training.
More specifically, improving pharmaco-education about PrEP may be an important first step to
strengthening physicians’ willingness to prescribe the medication. Based on the results from
questions inquiring about participants’ perceptions of PrEP’s safety and effectiveness,
misconceptions or substantial concerns about the drug’s effect on patients seem to exist. For
example, only 28.8% of participants perceived PrEP to be very safe, despite evidence that the
medication has a good safety profile and is well-tolerated.35 It is possible that this result may
reflect participants viewing “safety” as related to factors like antiretroviral drug resistance or
possible increases in patients’ risky sexual behavior, rather than the medication’s
pharmacological safety profile. Still, a substantial portion of our sample reported being
concerned about PrEP’s side effects (62.1%) and the potential toxicity of the medication for
patients (37.1%), indicating that concerns about the drug’s direct impact on patients’ health do
exist. In terms of effectiveness, approximately 9% of participants viewed PrEP as either slightly
effective or not effective at all, even though there now exists a large body of evidence that
demonstrates its efficacy when patients remain adherent to the medication.9–12 Additionally,
44.7% of participants cited the effectiveness of PrEP as a concern they had about the drug. From
these findings we see a consistent pattern of a proportion of physicians questioning the safety of
PrEP, as well as its ability to effectively prevent HIV. As such, we believe that improving
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physicians’ knowledge on the safety profile of PrEP, the prevalence and extent of drug-related
side effects, and the effectiveness of PrEP in various settings for different populations is an
important step towards enhancing physicians’ openness to prescribing the medication.
Given the potential impact that improvements in medical education on PrEP can have for
enhancing willingness to prescribe, the fact that 73.5% of our sample is at least somewhat
willing to attend CME on PrEP (40.9% of the total sample were very willing), makes the
implementation of educational interventions a compelling possibility. Also, because willingness
to attend CME was significantly associated with willingness to prescribe PrEP in both our
bivariate and multivariable models, encouraging and supporting interest in CME on PrEP may
also serve to improve people’s openness to prescribing. Importantly, to help support the interest
and accessibility of CME, research should be conducted to identify how to best implement a
PrEP CME course so that physicians—who often have demanding work schedules—are
motivated and easily able to participate.
Beyond supporting and improving education on PrEP, addressing physicians’ concerns related to
risk compensation may be another important step to enhancing willingness to prescribe PrEP.
Risk compensation describes a phenomenon where individuals accept a certain level of perceived
risk to their health so that they can enjoy the perceived benefits of a particular activity.36 When
an intervention that reduces perceived risk is implemented, a person may then increase their risk
behavior to maintain the same approximate “risk setpoint.” In the context of PrEP, risk
compensation often refers to a concern that those on the medication will alter their sexual
behavior now that the risk of acquiring HIV has decreased.37,38 It is believed that this change in
risk perception may lead to decreases in condom use or new engagement in other sexual
behaviors that could facilitate transmission of STIs. Indeed, some of the most frequently cited
17

concerns by our sample included a worry that PrEP use will lead to a decrease in condom use
(76.5%), an increase in STIs (50.0%), and an increase in patients’ number of sexual partners
(44.7%). Such results are similar to findings from other studies where physicians commonly cite
a fear of risk compensation as a barrier to prescribing PrEP.22,24–27 Evidence of risk
compensation actually occurring after PrEP initiation is mixed. For example, several clinical
trials on PrEP reported no substantial changes in STI incidence or sexual behavior after PrEP
initiation, while a systematic review of 17 open-label studies found that use of PrEP was
associated with increases in STI diagnoses for MSM.39–42 Attempting to assess evidence for risk
compensation is further complicated by the potential confounding effects of increased STI
testing for PrEP users, background changes in population STI rates, and the incorporation of
counseling on risk behaviors in some PrEP trials and demonstration projects.37,40,43
While evidence for risk compensation may currently be inconclusive, addressing concerns that
physicians have about it is still critical for improving PrEP dissemination. One possible strategy
for alleviating physicians’ concerns could be to encourage the prescription of PrEP within a more
comprehensive care plan which incorporates repeat STI testing, risk counseling, and
motivational interviewing for interested patients. This may reduce concerns about the
consequences of potential behavioral changes for individuals who use PrEP. Additionally, while
many physicians may be concerned about the impact of PrEP on the incidence of other STIs, it is
important for public health messaging to continue to emphasize the medication’s efficacy in
preventing incidence of HIV. The role of PrEP in further supporting the sexual health of those
who may either face challenges in consistently using condoms or who may prefer to incorporate
additional prevention strategies, should not be understated particularly since a belief that PrEP
was essential for addressing the HIV epidemic was strongly associated with willingness to
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prescribe in our sample. Ultimately, working to reframe PrEP from a drug which may encourage
individuals to replace one risk for another, to a drug which has a unique and specific role in
supporting some individuals’ sexual health, is a potentially important move for enhancing
physicians’ support of PrEP.
When focusing on what our results mean for physicians’ openness to prescribing PrEP to patients
from specific populations, the majority of the sample reported being likely to prescribe to
patients from all of the 4 key populations. More specifically, over 80% of the sample expressed
they were likely to prescribe PrEP to MSM, TGW, and SW. The population where likelihood of
prescribing was notably lower were PWID where only 66.7% of physicians claimed they would
be likely to prescribe to a patient who injected drugs, and 15.2% reported being unlikely to
prescribe. In contrast, the proportion of physicians unlikely to prescribe to every other key
population was less than 10%. This may not be particularly surprising since the average attitude
score towards PWID was substantially lower compared to other key populations (Table 3).
While attitudes towards these different key populations were not significantly associated with
general willingness to prescribe PrEP in our regression models, we found that they did have a
weak, but significant positive correlation with likelihood of prescribing to individuals from that
specific population. As such, it may be important to address negative attitudes towards different
key populations in an effort to improve the possibility that individuals can more easily access
PrEP if they wish to do so. Potential strategies for improving physicians’ attitudes could include
ensuring that clinicians are provided with accurate, destigmatizing information about key
populations as well as opportunities for clinical interaction with patients from these populations
during medical school and through CME. The need for such education is substantial as 83.3% of
our sample reported that they did not feel that medical professionals receive enough education on
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MSM, TGW, SW, and PWID. Additionally, contact theory posits that increasing one group’s
exposure to another may help reduce intergroup prejudice and several studies have presented
evidence of this phenomenon for a diversity of populations.44,45 The impact of contact-based
interventions on medical professionals’ attitudes towards stigmatized populations has also been
explored, typically by providing medical students with opportunities to meet and/or provide care
to a member of a stigmatized group.46–49 Such interventions have demonstrated that these
interactions can improve providers’ attitudes towards a group and positively influence their
views on appropriate patient care, making their incorporation into medical training in Thailand a
compelling possibility. Ultimately, educational interventions which increase academic and
clinical exposure to different key populations may help reduce stigmatizing attitudes towards
these groups and subsequently improve the likelihood that physicians would be open to
prescribing PrEP to members of these key populations.
There were several limitations to this study. First, participants were recruited through
convenience sampling, and as such, the results from this study are not necessarily generalizable
to the general population of physicians in Thailand. Those who participated in this study may be
unique in their interest in PrEP, and we cannot rule out the possibility that they may be more or
less willing to prescribe the medication when compared to their peers who did not participate.
There is also the possibility that social desirability bias impacted participants’ responses to
questions inquiring about their willingness to prescribe, willingness to attend further medical
education, and their attitudes towards key populations. By making the survey anonymous, we
attempted to reduce this possibility, but we cannot be sure that it did not impact our results.
Additionally, while the survey link was disseminated through private Facebook groups dedicated
to licensed physicians in Thailand, we had no way of confirming that all participants did meet
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our established inclusion criteria. Finally, our sample included physicians from a variety of
medical specialties and did not specifically target those who may be most likely to currently be
in a position to prescribe PrEP in Thailand. Further studies should attempt to target and
understand the attitudes and behaviors of providers who practice in medical fields that are
uniquely qualified for prescribing PrEP and that may have more PrEP-related content in their
medical training.

Conclusions
Despite the limitations of this study, we believe it is the first to formally evaluate physicians’
willingness to prescribe PrEP in Thailand. These results indicate a general willingness to
prescribe PrEP—particularly amongst those who see PrEP as essential for addressing the HIV
epidemic and those who are willing to dedicate time to learning more about the medication.
Importantly, our findings also highlight Thai physicians’ concerns about PrEP, the perceived
barriers to prescribing, and discrepancies in their likelihood of prescribing to different
populations. From these findings, targeted educational and clinical interventions that address
some of these challenges to encouraging willingness to prescribe can be developed. Future
research should investigate these patterns among specific specialties of physicians and among a
larger, random sample of participants. Additionally, exploring similar questions through
qualitative methods may provide more insight on physicians’ knowledge and attitudes about
PrEP and their potential motivation to prescribe PrEP to patients from different populations.
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Appendix
Table 1. Characteristics of study population (n=132)
Characteristic
Age (years), mean ± SD
Years practicing, mean ± SD
Gender
Man
Woman
Non-binary gender
Experience prescribing PrEP
Yes
No
Specialty
General practice
Family Medicine
Internal Medicine
Obstetrics/Gynecology
Emergency Medicine
Infectious Disease
Other
Place of employment
Private hospital
Teaching/University hospital
Government provincial hospital
Government district hospital
Private clinic
Other government hospitals
Primary Care Unit/CHC
Other

N (%)*
39.5 ± 9.2
14.0 ± 8.6
67 (50.8)
64 (48.5)
1 (0.7)
24 (18.2)
108 (81.8)
39 (29.5)
19 (14.4)
15 (11.4)
10 (7.6)
4 (3.0)
1 (0.8)
44 (33.3)
26 (19.7)
22 (16.7)
20 (15.2)
19 (14.4)
16 (12.1)
15 (11.4)
10 (7.6)
4 (3.0)

*Percentages may not sum to 100% due to rounding
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Table 2: Pearson correlations: feelings towards key population and likelihood of prescribing to individuals in
that population (n =132)*
r (95% CI)

p

MSM

0.20 (0.03, 0.36)

0.02

TGW

0.21 (0.04, 0.37)

0.02

SW

0.17 (>0.00, 0.33)

0.049

PWID

0.26 (0.10, 0.41)

<0.01

*Key: r = Pearson’s correlation coefficient; CI = confidence interval; MSM = men who have sex with men;
TGW = transgender women; SW = sex workers; PWID = people who inject drugs.
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Table 3: Unadjusted and adjusted associations between study variables and willingness to prescribe (n =132)*
Characteristic

Mean
(SD)
Sociodemographic and professional factors
Age
39.5 (9.2)
Years practicing
14.0 (8.6)
Man
Practices in public sector
Primary care
Attitude score for relevant populations
PLWHIV
70.1 (21.1)
MSM
63.1 (21.9)
TGW
63.0 (20.7)
SW
55.2 (24.2)
PWID
34.6 (28.9)
Feelings about the HIV epidemic
Believes PrEP is essential for
addressing epidemic
Very concerned about the HIV
epidemic
Concerns and opinions about PrEP
Concern: Condom use will decrease
Concern: ARV resistance
Concern: Patient compliance
Concern: Side effects
Concern: STIs will increase
Believes PrEP is very safe
Believes PrEP is very effective
Barrier: Insufficient clinical
knowledge of PrEP
Willing to attend CME for PrEP
Clinical practice
Asks about patients’ sexual histories
Refers for HIV testing
Clinical experiences with PrEP
Prior awareness of PrEP
Previously prescribed PrEP

N (%)

Unadjusted OR
(95% CI)

p

Adjusted OR
(95% CI)

p

0.98 (0.94, 1.02)
0.99 (0.94, 1.03)
1.59 (0.76, 3.34)
1.05 (0.51 2.19)
1.31 (0.63, 2.73)

0.27
0.49
0.22
0.89
0.47

1.02 (1.005, 1.04)
1.02 (0.998, 1.03)
1.01 (0.995, 1.03)
1.01 (0.998, 1.03)
1.00 (0.996, 1.02)

0.01
0.08
0.14
0.08
0.18

1.02 (0.995, 1.04)

0.12

113 (85.6)

29.92 (6.47, 138.28)

<0.01

20.87 (3.69, 118.12)

<0.01

51 (38.6)

1.20 (0.56, 2.56)

0.64

101 (76.5)
94 (71.2)
87 (65.9)
82 (62.1)
66 (50.0)
38 (28.8)
47 (35.6)
56 (42.4)

0.69 (0.28, 1.70)
0.99 (0.44, 2.21)
1.29 (0.60, 2.78)
1.18 (0.55, 2.49)
0.66 (0.31, 1.34)
2.63 (1.05, 6.60)
4.00 (1.61, 9.96)
0.636 (0.304, 1.332)

0.41
0.97
0.51
0.67
0.26
0.04
<0.01
0.23

1.20 (0.312, 4.57)
1.47 (0.41, 5.26)

0.79
0.56

97 (73.5)

11.77 (4.78, 28.97)

<0.01

9.46 (3.27, 27.3)

<0.01

92 (69.7)
115 (87.1)

1.98 (0.91, 4.31)
2.12 (0.75, 5.95)

0.08
0.15

107 (81.1)

4.44 (1.79, 11.06)

<0.01

3.43 (0.96, 12.22)

0.06

24 (18.2)

2.71 (0.87, 8.52)

0.09

67 (50.8)
64 (48.5)
73 (55.3)

*Key: SD = standard deviation; OR = odds ratio; CI = confidence interval; PLWHIV = people living with HIV; MSM =
men who have sex with men; TGW = transgender women; SW = sex workers; PWID = people who inject drugs; ARV=
antiretroviral; CME = continuing medical education.
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Figure 1. Concerns about PrEP (n = 132)

Patients will not use condoms

76.52
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71.21
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62.12

Increase in STIs

50.00
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44.70
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44.70
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Other*
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90.00

100.00

Percent (%)
*Other concerns that participants described include a concern about the lack of long-term data on PrEP, potentially having to diagnose
patients with HIV if PrEP fails, the general “social problems” PrEP will cause, and a concern that PrEP will diminish the importance of a
“universal precautions” approach
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Figure 2: Single most significant barrier to prescribing PrEP (n = 132)

Insufficient clinical knowledge

42.42

Lack of clinical guidelines
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*Other barriers that participants described include the perceived difficulty of prescribing PrEP in primary care settings, the possibility of
having to diagnose a patient with HIV if PrEP fails, the inability of PrEP to prevent other STIs, and a preference for promoting barrier
methods for HIV prevention.
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Figure 3: Willingness to prescribe (n = 132)

50.00
45.00
40.00

39.39

35.00
28.79

30.00

25.00
25.00
20.00
15.00
10.00

6.82

5.00
0.00
Very willing

Somewhat willing

Not very willing

Unwilling

Percent (%)

27

Figure 4: Likelihood of prescribing PrEP to different populations (n = 132)*

Very likely

MSM
0.76
3.03

54.55

32.58

9.09
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Neutral
Unlikely
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13.64

2.27
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SW
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6.06
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18.18
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Percent (%)
*Key: MSM = men who have sex with men; TGW = transgender women; SW = sex workers; PWID = people who inject drugs.
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